AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
Audio long read: The ‘breakthrough’ obesity drugs that have stunned researchers
Nature Podcast
Tezepitide Is a GLP1 Imitator
Eli Lilly plans to apply for the drug to be approved, pending results from a second phase 3 trial wrapping up in April 2023. The levels of weight loss following Tezepitide treatment approach those typically achievable only through bariatric surgery. This procedure reduces body weight by 30% or more after 6 months, and the weight loss continues for the next year or two.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode